Endoglin antibodies

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8221753
APP PUB NO 20110076263A1
SERIAL NO

12751907

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
KAIROS PHARMA LTD2355 WESTWOOD BLVD #139 LOS ANGELES CA 90064

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Theuer, Charles San Diego, US 13 147
Vasquez, Maximiliano Palo Alto, US 92 2096

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation